Holton C P, Burrington J D, Hatch E I
Cancer. 1975 Apr;35(4):1083-7. doi: 10.1002/1097-0142(197504)35:4<1083::aid-cncr2820350410>3.0.co;2-k.
In 1970, a staging based on surgical resectability of hepatic tumors was devised. Adjuvant chemotherapy with vincristine, 5-fluorouracil, and cyclophosphamide has been given to seven recent cases. Objectives of this study were to set up unified clinical staging and followup; to evaluate the effect of combination chemotherapy on survival in advanced disease; and to evaluate early adjunctive combination chemotherapy in surgically resectable lesions to, hopefully, prevent metastasis. Results to date in seven patients are: no change in the poor prognosis of the three female patients presenting with Stage III-IV hepatocellular carcinoma; the three males with Stage I-II hepatoblastoma have done well and survive the free of disease at 47 months, 44 months, and 28 months; one patient with hepatoblastoma had lung metastasis at diagnosis and died at 7 months with tumor. No toxicity was noted with the use of adjunctive combination chemotherapy following major hepatic resection.
1970年，设计了一种基于肝肿瘤手术可切除性的分期方法。最近对7例患者给予了长春新碱、5-氟尿嘧啶和环磷酰胺辅助化疗。本研究的目的是建立统一的临床分期和随访；评估联合化疗对晚期疾病患者生存的影响；评估在可手术切除病变中早期辅助联合化疗以有望预防转移的效果。目前7例患者的结果如下：3例III-IV期肝细胞癌女性患者的不良预后无变化；3例I-II期肝母细胞瘤男性患者情况良好，分别在47个月、44个月和28个月时无病存活；1例肝母细胞瘤患者在诊断时已有肺转移，7个月时因肿瘤死亡。在肝大部切除术后使用辅助联合化疗未观察到毒性反应。
